"Fewer than 3 in 10 younger women with early-stage, hormone-driven breast cancer consistently complete five years of prescribed hormone therapy, a critical treatment for preventing recurrence. This real-world data highlights a significant gap between treatment recommendation and patient adherence, particularly when radiation therapy is omitted."
A recent insurance claims analysis, presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, has illuminated a concerning trend in breast cancer treatment adherence. The study revealed that a mere 28% of patients under 65, diagnosed with early-stage, hormone receptor-positive breast cancer, maintained consistent prescription refills for their hormone therapy over the recommended five-year period following a lumpectomy. This finding underscores a critical disconnect between the prescribed treatment and its actual completion, raising significant questions about the long-term management of this common cancer subtype. The analysis, based on pharmacy refill records from over 17,000 patients, provides a stark glimpse into the challenges faced by individuals navigating the complex landscape of cancer survivorship and the vital role of sustained medication use in preventing disease recurrence.
The findings, presented on September 27th at the prestigious ASTRO Annual Meeting, are currently awaiting peer-reviewed publication. The research, led by Dr. Shannon Jiang, a radiation oncology resident at Washington University School of Medicine in St. Louis, meticulously examined pharmacy refill data from a large cohort of 17,025 patients aged 23 to 64. These individuals had all undergone a lumpectomy for early-stage, hormone receptor-positive breast cancer and had filled at least one prescription for hormone therapy. Crucially, approximately 89% of these patients also received radiation therapy as part of their treatment regimen.
The study defined adherence as having medication available at least 80% of the time. While yearly snapshots of patient behavior revealed a more optimistic picture, with 59% to 75% meeting this adherence threshold in any given year, the long-term picture painted a more troubling reality. Over the full five-year period, a steady decline in consistent medication availability was observed, culminating in only about 28% of patients remaining continuously adherent. This significant drop-off over time suggests that while initial commitment to treatment may be high, maintaining this commitment for the entirety of the recommended duration proves to be a substantial hurdle for a majority of patients.
Further dissecting the data, researchers identified that patients younger than 60 faced a 20% to 25% higher risk of becoming nonadherent compared to their older counterparts. This age-related disparity warrants further investigation, potentially pointing to specific challenges faced by younger individuals in managing long-term medication regimens, such as career demands, family responsibilities, or differing perceptions of risk. Dr. Jiang aptly summarized the core issue, stating, "Our findings are a reminder that doctors prescribing endocrine therapy for five years and patients actually taking the medication for five years are not the same thing." This simple yet profound statement encapsulates the gap between clinical intent and real-world execution, emphasizing the need for robust strategies to bridge this divide.
Endocrine therapy plays a pivotal role in treating hormone receptor-positive breast cancers, which constitute approximately 80% of all breast cancer diagnoses. These therapies work by either blocking the action of hormones like estrogen or by lowering the body’s production of these hormones, thereby starving the cancer cells of the fuel they need to grow and proliferate. Common endocrine therapies include tamoxifen and aromatase inhibitors such as anastrozole, letrozole, and exemestane. These medications are typically prescribed as daily pills and are recommended for a duration of at least five years to significantly reduce the risk of cancer recurrence. Interruptions in this treatment, even for short periods, can leave patients vulnerable, allowing cancer cells that may have evaded initial treatment to potentially regrow.
The study also shed light on the intricate relationship between radiation therapy and endocrine therapy adherence, particularly in the context of omitting radiation. Clinical trials, such as the PRIME II trial involving women aged 65 and older, have demonstrated that for certain lower-risk tumors, radiation can be safely omitted without compromising overall survival, although the risk of local recurrence in the treated breast increases. In the PRIME II trial, the 10-year local recurrence rate was 9.5% without radiation compared to 0.9% with radiation, while overall survival remained nearly identical. Importantly, patients in this trial were expected to continue with hormone therapy.
In the ASTRO analysis, patients who did not receive radiation therapy exhibited a notably higher likelihood of falling below medication possession levels of 50%, 60%, and 70%. While the difference did not reach statistical significance at the standard 80% adherence threshold, this trend suggests a potential association between omitting radiation and a greater propensity for substantial gaps in endocrine therapy. The study authors acknowledge that the precise reasons for this association remain unclear and were not designed to establish causality. Potential explanations include more frequent interactions with healthcare providers for patients undergoing radiation, which might foster greater adherence, or pre-existing differences in access to care or patient preferences between the two groups.
As research continues to explore the possibility of omitting radiation therapy in younger women with favorable tumor characteristics, understanding long-term endocrine therapy adherence in real-world settings becomes increasingly critical. Dr. Jiang emphasized this point, stating, "As studies expand radiation therapy omission to younger patients with favorable tumors, it becomes increasingly important to understand what happens with long-term adherence to endocrine therapy in real-world settings." This growing clinical question highlights the need for proactive strategies to support patients in completing their prescribed treatment regimens.
Dr. Jose G. Bazan, chair of ASTRO’s Breast Cancer Resource Panel and a radiation oncologist at City of Hope in Duarte, California, commented on the study’s implications, noting that it "shows how difficult long-term adherence can be." He further stressed the importance of "choosing a treatment plan that patients can realistically maintain over time." This perspective underscores a patient-centered approach to cancer care, where treatment decisions are not solely based on efficacy but also on the patient’s ability and willingness to adhere to the prescribed regimen.
It is crucial to acknowledge the limitations of this observational study, which was presented as a meeting abstract. While it identified an association between omitting radiation and lower adherence, it cannot definitively prove that radiation therapy directly causes improved adherence to endocrine therapy. Furthermore, the study’s database did not include individuals older than 64, a demographic that represents a significant portion of the population currently considered for radiation omission. The research team plans to expand their analysis by incorporating Medicare data to address this gap. Additionally, pharmacy refill records, by their nature, cannot account for doses that patients may have skipped after picking up their prescriptions.
The patterns observed in this study are consistent with prior research on endocrine therapy adherence. A 2014 review published in Cancer Prevention Research estimated that only about half of women complete five years of adjuvant hormone therapy in routine practice. This review linked nonadherence to various factors, including medication costs, patient age (both younger and older), and suboptimal patient-doctor communication. A subsequent systematic review of adherence interventions highlighted nonadherence as a significant problem, particularly within minority populations, suggesting that socioeconomic and cultural factors may also play a role.
The decision to initiate and maintain long-term hormone therapy is often influenced by the potential side effects associated with these medications. Tamoxifen can cause side effects such as hot flashes and vaginal discharge. Aromatase inhibitors, on the other hand, are associated with a broader range of side effects, including joint and muscle pain, hot flashes, vaginal dryness, and bone thinning. For some patients, the joint stiffness and pain can become severe enough to prompt discontinuation of treatment.
It is imperative that patients do not stop or pause their hormone therapy without consulting their oncologist. Open and early communication with healthcare providers about any side effects experienced is crucial. Oncologists can offer a range of strategies to manage these side effects, including symptom-specific treatments or switching to an alternative medication that may be better tolerated. Practical interventions such as refill reminders, pharmacy auto-refill programs, and obtaining 90-day supplies can also help prevent gaps in medication availability. For patients facing financial constraints due to high co-pays, discussing the availability of generic versions of medications or exploring financial assistance programs can be vital in ensuring treatment continuity.
For individuals contemplating whether to forgo radiation therapy, a thorough discussion with their care team is essential. This conversation should encompass the realistic likelihood of adhering to five years of daily medication and how the risk of cancer recurrence might be impacted by the presence or absence of radiation. Caregivers can also play a supportive role by assisting patients in tracking medication refills and ensuring timely renewal of prescriptions.
The ASTRO presentation serves as a crucial stepping stone, and future peer-reviewed publication of these findings, along with the planned incorporation of Medicare data, will provide a more comprehensive understanding of long-term adherence patterns in diverse patient populations. The ongoing dialogue surrounding these findings is vital for refining treatment strategies and developing effective interventions to support breast cancer survivors in completing their prescribed therapy, thereby maximizing their chances of long-term health and well-being.
Key Questions Answered:
What did the study find? Approximately 28% of patients under 65 consistently adhered to their five-year hormone therapy regimen after lumpectomy, based on insurance refill records.
Who was studied? The analysis included 17,025 patients aged 23 to 64 with early-stage, hormone receptor-positive breast cancer who were covered by commercial insurance or Medicaid.
Did skipping radiation lower adherence? Patients who omitted radiation therapy were more likely to experience significant gaps in their medication supply. However, the study does not establish a causal link between radiation therapy and improved endocrine therapy adherence.
Is the study peer-reviewed? No, the study was presented as a meeting abstract at the ASTRO Annual Meeting in Boston on September 27th and is awaiting peer-reviewed publication.
Why do patients stop hormone therapy? Factors linked to nonadherence include medication side effects such as hot flashes and joint pain, as well as cost, age, and communication challenges with healthcare providers.
Should I stop my medication if side effects are hard? No. It is essential to discuss any difficult side effects with your oncologist. Side effects can often be managed, or alternative medications may be available.
